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Abstract
In the present study we aimed to determine the prevalence of C9ORF72 GGGGCC hexanucleotide
expansion in our cohort of 53 FTLD patients and 174 neurologically normal controls. We
identified the hexanucleotide repeat, in the pathogenic range, in 4 (2 bv-FTD and 2 FTD-ALS) out
of 53 patients and one neurologically normal control. Interestingly, two of the C9ORF72
expansion carriers also carried two novel missense mutations in GRN (Y294C) and in PSEN-2
(I146V). Further, one of the C9ORF72 expansion carriers, for whom pathology was available,
showed amyloid plaques and tangles in addition to TDP-43 pathology. In summary, our findings
suggest that the hexanucleotide expansion is probably associated with ALS, FTD or FTD-ALS
and occasional comorbid conditions such as Alzheimer’s disease. These findings are novel and
need to be cautiously interpreted and most importantly replicated in larger numbers of samples.
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Introduction
Frontotemporal lobar degeneration (FTLD, OMIM #600274) is the second most common
cause of presenile dementia. It is characterized by progressive degeneration of the frontal
and anterior temporal lobes of the brain leading to wide range of clinical symptoms
including changes in personality and behavior, language impairment, and cognitive
dysfunction (reviewed in Ferrari et al. 2011). Approximately 15% of FTLD patients develop
symptoms of motor neuron dysfunction (Lomen-Hoerth et al., 2002). The co-occurrence of
FTLD and MND in familial cases suggests that FTLD represents a spectrum of neurological
disorders with complicated clinical, pathological and genetic etiology. The most common
form of FTLD pathology is FTLD-TDP with TAR DNA-binding protein-43 (TDP-43)
immunoreactive neurons, which is also deposited in neurons of ALS patients. This
pathological finding links FTLD and ALS (Neumnann et al., 2006; Arai et al., 2006).
To date, mutations in the progranulin gene (GRN) are considered the most prevalent and
encompass phenotypes from bvFTD to CBS. The common pathology in GRN mutation
carriers is TDP-43 positive inclusions. Mutations in the TDP-43 gene however, are usually
associated with the ALS phenotype (Corrado et al. 2009) and rarely found in FTLD (Borroni
et al. 2009) or CBS (Huey et al. 2011). The causal link between the mutations in GRN gene
and TDP-43 pathology is yet to be established. Mutations in the other FTLD candidate
genes, MAPT, VCP, CHMP2B, PSEN1, and PSEN2 explain only very small number of
FTLD patients and there is no report of ALS or MND among those mutation carriers.
Linkage studies of cases with ALS, FTD, FTD-ALS with type 2 TDP-43 pathology had
suggested a locus on chromosome 9p (Boxer et al., 2011; Morita et al., 2006; Vance et al.,
2006) although it was not clear if the GWA and the linkage studies identified the same locus
on 9p. Mok et al. in 2011 suggested a common founder for FTLD and ALS on chromosome
9, based on the original Finnish association study reported by Laaksovirta et al in 2010. The
identification of hexanucleotide GGGGCC repeat expansion in the non-coding region of
C9ORF72 in families linked to 9p21 (DeJesus-Hernandez et al., 2011; Renton et al., 2011)
suggested this expansion as a possible cause of FTLD and ALS.
In the present study we screened 53 patients and 174 neurologically normal controls for the
expansion of the GGGGCC hexanucleotide. Our cohort encompasses a wide range of the
FTLD spectrum which may prove useful in establishing a phenotype/genotype correlation
within the FTLD spectrum. In the present study, we identified 4 out of 53 patients and one
neurologically normal control who had donated a sample to the Coriell institute who carried
the hexanucleotide repeat in the apparent pathogenic range.
Patients and methods
Patients
The study population comprised a sub-group of patients which have been previously
described (Huey et al. 2011), consisting of 27 probable bv-FTD, 9 possible bv-FTD, 6 PPA-
PNFA, 2 PPA-semantic, 4 FTD-ALS, 4 AD, and 1 MSA diagnosed using appropriate
criteria (Neary et al., 1998; Raskovcky et al., Brain 2011; McKhann et al., 1984; Gilman et
al., 2008). A full neurological and neuropsychological evaluation was performed for all
patients. Table 1 presents a brief family history of all patients.
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Genetic screening
Blood samples from index patients were collected in accordance with the local Institutional
Review Board guidelines and informed written consent form was obtained. The DNA of all
patients was screened for MAPT, PGRN, FUS, TDP43, PSEN1, PSEN2, APP and
CHMP2B. In order to screen for hexanucleotide expansions in the C9ORF72 gene, we
performed the experiments as described in Renton et al. (2011). Although this method is not
able to determine the exact number of repeats, it can detect repeat numbers of maximum ~
60. This method however, can discriminate the normal repeat range detected in the normal
population (0-20) from the higher mutated range (≥30). Renton et al. (2011) detected a
pathogenic repeat number of ~250 repeats in a carrier whose fluorescence in situ
hybridization (FISH) analysis verified the repeat expansion. DeJesus-Hernandez et al.
(2011) used a different method to amplify the repeat region of C9ORF72 and for the
verification of repeat size they subsequently performed Southern blot analysis. They
estimated the number of repeats between 700-1600. As the goal of our study was solely to
determine if our cohort has repeat numbers above the range of normal controls, we screened
the DNA of 53 patients and 174 neurologically normal controls from Coriell Institute
(NDPT 098 and 099). The mutated alleles were considered at the length of 30 repeats and
above (Renton et al., 2011). The DNA of these patients had been genotyped on the illumina
infinium platform as part of the ongoing international FTD-GWAS consortium project. The
genotypes of 42 SNPs which were used to build the chromosome 9p21 haplotype in Finnish
population (Laaksovirta et al., 2010) were derived from the GWAS data for the 53 patients
to determine if the carriers of the expansion also harbor the same ancestral haplotype as the
Finnish carriers of hexanucleotide expansion.
Results
In our cohort we identified 4 out of 53 patients (FTD158, FTD198, FTD211 and FTD223)
and one out of 174 neurologically normal controls (Coriell plate NDPT099 - ND07551) with
repeat expansion in the pathogenic range (≥30) (Figure 1). Among the carriers of the
hexanucleotide expansion, one patient (case 1 FTD158) carries a novel GRN mutation
Y294C (Figure 2A) and another patient (case 4 FTD223) carries a novel mutation in PSEN2
I146V (Figure 2B). None of these mutations have been reported previously and there is no
functional data available regarding pathogenicity of these variants. Due to lack of
informative family members, we could not examine the segregation of these mutations with
the disease. The in silico analysis by PolyPhen-2 software (PolyPhen-2: http://
genetics.bwh.harvard.edu/pph2/) predicted both variants to be probably damaging.
We extracted the genotypes of 42 SNPs of the original Finnish haplotype by Laaksovirta et
al 2010 to determine if our patients harbor the original risk haplotype on chr9p21 for FTD-
ALS (rs3849942, rs1330921, rs10121765, rs1110264, rs1110155, rs2150336, rs2225389,
rs1161680, rs2120718, rs2589054, rs10812596, rs1058326, rs944404, rs765709, rs1316679,
rs4406503, rs10511817, rs725804, rs10511816, rs1444533, rs1822723, rs4879515,
rs895023, rs868856, rs7046653, rs2440622, rs1977661, rs903603, rs10812610, rs2814707,
rs12349820, rs10122902, rs10757665, rs1565948, rs774359, rs2282241, rs1948522,
rs1982915, rs2453556, rs702231, rs696826, rs2477518). Our genotyping (Supplementary
Table 1) revealed that the complete risk haplotype does not exist in any of our patients.
However, Renton et al 2011 reported that SNP rs3849942 is a surrogate marker for the risk
haplotype in the populations that they studied. Our 4 patients with expansions carry the risk
allele A (rs3849942) and 20 out of 49 of the rest of patients without expansion carry that risk
allele as well. Of note, in our patients series there were two individuals diagnosed with FTD-
MND, samples FTD134 and FTD163 (Table 1). Patient FTD134 carries neither the
expansion nor the risk allele A (rs3849942), while FTD163 does not carry the expansion but
the risk allele.
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The family history of the patients who carry the hexanucleotide repeat expansion can be
seen in more detail in the pedigrees (Figure 3). A full clinical description of these four
patients can be found in the supplementary clinical data.
Discussion
Our cohort of FTLD patients was recruited from around the country and was not selected on
the basis of family history, known familial mutations, or presence of MND. This sample is
likely representative of the general U.S. FTLD population. In the quest to identify the
genetic cause of FTLD in our cohort, we screened 53 of our patients for the newly identified
locus on chromosome 9p21 (DeJesus et al., 2011; Renton et al., 2011). Patients were
referred to NIH primarily with symptoms of frontotemporal dementia and some had
developed accompanying neuropsychiatric or motor neuron symptoms as well (Table 1). We
identified hexanucleotide expansion of over 30 repeats in 4 patients of which two have a
diagnosis of FTD-ALS and two of bv-FTD. As our mutation finding did not reach the
statistical significance of the original publications by DeJesus-Hernandez et al. and Renton
et al., we aimed to verify the existence of the risk haplotype in our population
(Supplementary Table 1). However, neither the risk alleles of the 42 SNPs of the original
Finnish risk haplotype (Laaksovirta et al., 2010), nor the phenotypes of the mutation carriers
showed a strong correlation to the hexanucleotide expansion compared to those who did not
carry the mutation. Among our 53 patients, no one carries the exact same Finnish risk
haplotype. Considering the fact that our patients are all recruited in the U.S. and have
diverse ethnic background this outcome is not unusual. The haplotype can be explained as a
possible genetic background for the carriers of the expansion and not necessarily associated
with the hexanucleotide expansion. The phenotype of our cohort was also diverse. As
reported previously (DeJesus-Hernandez et al., 2011 Renton et al., 2011; Gliselnick et al.,
2011; Troakes et al., 2011), the expansion is detected mainly in FTD-MND cases. As
evident in Tables 1 and 2 we had overall 4 patients with FTD-ALS or FTD-MND (of which
only two, FTD211 and FTD223, carried the expansion) and 2 bv-FTD cases with family
history of ALS (FTD183 and FTD218) who did not carry the hexanucleotide expansion.
Additionally, we identified the expansion of more than 45 in one neurologically normal
control (see Supplementary clinical data). These findings prompt us to have a more critical
view to understand whether the C9ORF72 hexanucleotide repeat expansion is the
pathogenic cause of the disease or merely a risk factor contributing to the susceptibility to
the disease. As we have previously shown (Huey et al., 2011) in cases such as FUS gene, the
variants which were originally reported as pathogenic in ALS cases were later found also in
neurologically normal controls. Furthermore, we replicated an interesting finding by Murray
et al (Table 2): the C9ORF72 expansion carriers may be more likely to present with memory
and psychiatric symptoms rather than typical FTLD symptoms. One of our C9ORF72
expansion positive patients presented with paranoia as his predominant symptom and two
others demonstrated significantly impaired memory. The one patient whose autopsy report is
available (FTD211) showed amyloid plaques and tangles in addition to TDP-43 pathology
(Dr. Ghetti personal communication). Murray et al. also describes one expansion case with
both TDP-43 and AD pathology. This suggests that the hexanucleotide expansion may also
coexist with forms of dementia other than ALS, FTLD, or FTD-ALS. Although this is only a
single case it raises the possibility that some cases of clinical and pathologic TDP-43
positive AD may be associated with C9ORF72 expansions. This association is proven best
through screening of pathologically confirmed AD cases which would link C9ORF72
expansions to AD as a cause of the disease, if confirmed.
Lastly, it is notable that we found two missense mutations, Y294C in GRN and I146V in
PSEN2, in two of our hexanucleotide expansion carriers (FTD158 and FTD223) which had
not been reported previously. There are several possible interpretations of this finding: 1.
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These missense mutations are benign and the disease is caused by the C9ORF72 expansion.
However, it seems unlikely that this is the case because we found the expansion in a
neurologically normal control and also because, although these two missense mutations are
novel and have not been previously reported, in silico analysis by Polyphen 2 predicts
highest level of pathogenicity for these two variants. Moreover, while GRN missense
mutations have not been considered as a common cause of FTLD, PSEN2 missense
mutations have been indisputably shown to be pathogenic. 2. The GRN and PSEN2
missense mutations are the primary pathogenic causes of the disease in these two FTD
patients and the C9ORF72 expansion contributes to the disease as a risk factor, increasing
the susceptibility to the disease. 3. These are two complex cases where two comorbid
conditions are caused by two separate lines of genetic mutations, namely the missense
mutations on one hand and C9ORF72 expansion on the other hand. If this is the case, the
GRN mutation would most probably lead to TDP-43 pathology and the PSEN-2 mutation to
the amyloid plaques. These two patients will probably have an additional pathology due to
C9ORF72 expansion which is yet to be identified.
To conclude, in this study we report the presence of hexanucleotide repeats in two bv-FTD
cases, two FTD-ALS cases (one of which showed, at autopsy, FTLD-TDP type B and AD
pathology), and one neurologically normal control from Coriell cell repository. Our findings
suggest that the hexanucleotide expansion is probably associated with ALS, FTD or FTD-
ALS and occasional comorbid conditions such as Alzheimer’s disease as evident in our
pathologically confirmed case 3 (FTD211). These findings are novel and need to be
cautiously interpreted and most importantly replicated in larger numbers of samples.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The repeat-primed PCR reactions were run on ABI3730 DNA Analyzer .The results were
analyzed & visualized using Gene Mapper software. Fluorescence intensities are shown in
the vertical axis: the size marker is identified by orange vertical lines and the hexanucleotide
repeats that extend beyond the 300 bp marker are marked in blue. The range of > 30 repeats
is considered the threshold suggesting presence of expansion even though a direct and
precise relatedness between this method and the actual repeat size has not been established
yet being, as such, simply predictive of probable repeat expansion. In here, counts of
approximately > 45 or > 50 repeats are depicted for, respectively, samples FTD-158 (A),
FTD-198 (B), FTD-211 (C), FTD-223 (D) and for Coriell neurologically normal control
ND07551 (E).
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Figure 2.
Electropherograms of the two novel missense mutations found in PGRN (A) and in PSEN2
(B) in two of the hexanucleotide repeat carriers, respectively individuals FTD-158 (A) and
FTD-223 (B). Both missense mutations have not been previously reported. After in silico
analysis using Polyphen 2 software, both mutations have been predicted to be probably
damaging.
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Figure 3.
Pedigrees of the patients carrying the C9ORF72 hexanucleotide expansion. 3A: FTD158,
3B: FTD198, 3C: FTD211, 3D: FTD223.
FTD: Frontotemporal Dementia; ALS Amyotrophic Lateral Scelerosis; AD: Alzheimer’s
Disease; MS: Multiple Sclerosis; TIA: Transient Ischemic Attack; ADHD: Attention
Deficiency Hyperactivity Disorder; PD: Parkinson’s Disease.
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Table 1
Samples IDs with corresponding diagnosis, number of hexanucleotide expansion and a brief family history of
neurological disorders for each patient. Diagnoses are described following Rascovsky et al., 2011.
Patient
ID
Diagnosis Hexanucleotide
Repeats #
Family history of neurological disorders
158 Probable bv-
FTD
> 50 Father - AD; Brother - MS
198 Probable bv-
FTD
> 45 Brother - TIA; Brother - alcoholism; Daughter - migraines;
Paternal aunt - dementia
211 FTD-ALS > 50 Mother - ALS; Brother - alcoholism; Father - dementia;
Brother/Son - depression; Daughter - migraines, depression;
Son - anoxic at birth
223 FTD-ALS > 50 Mother - dementia; Father - dementia ; Sister - FTD ; Brother
- alcoholism ; Son - depression, drug use
81 Probable bv-
FTD
1 Father - died of dementia at 77
83 AD 7 Paternal grandfather - dementia
85 FTD-PPA 7 Father -vasc. dementia died at 68
88 FTD-PPA 14 Sister - PD
89 Probable bv-
FTD
8 Mother - LOAD; Paternal grandmother - dementia died at 89
90 Probable bv-
FTD
4 Father - CVA; Nephew - OCD
95 SD 4 Maternal aunt - dementia
96 Probable bv-
FTD
~ 25 Father - AD onset 58; Maternal uncle - schizophrenia
97 FTD-PPA 3 Son - schizophrenia
98 Possible
FTLD
15 Sister CVA. O/w no +FH
99 Probable bv-
FTD
10 Father - PD died at 85; Mother dementia, brain tumor; 3 aunts
- dementia; Maternal grandmother - dementia
101 Probable bv-
FTD
3 Son - schizophrenia, drug abuse; Daughter - schizophrenia;
Sister &Brrother - drug abuse
103 SD 5 Maternal grandmother - CVA; Maternal aunt - CVA
107 Probable bv-
FTD
1 Paternal uncle - unknown mental illness
111 Possible
FTLD
2 Sister - Korsakoff syndrome; Mother - OCD, depression;
Sister -alcoholism; Twin brother - alcoholism
114 FTD-PPA 2 Father - AD, PD died at 63; 2 brothers - schizophrenia
115 Probable bv-
FTD
6 Father - dementia onset at 72 paternal grandmother
Parkinson’s and memory problem died in her 70”s
118 Probable bv-
FTD
6 Father - AD; Mother - AD, depression both died in their early
90’s
123 Probable bv-
FTD
8 Brother - learning disabilities, alcoholism; Sister - eating
disorder, depression
124 Probable bv-
FTD
7 Father - PD; aunt AD died at 79
127 MSA 1 Mother - AD; Brother - CVA; Brother - brain cancer
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Patient
ID
Diagnosis Hexanucleotide
Repeats #
Family history of neurological disorders
128 Probable bv-
FTD
3 Father - OCD; Mother - Mental disorder NOS
134 FTD-MND 1
136 Probable bv-
FTD
2 Mother - dementia at 87; maternal uncle dementia
139 FTD-PPA 10 Mother - depression, alcoholism
143 Probable bv-
FTD
17 Daughter - OCD, depression
144 Probable bv-
FTD
5
163 FTD-MND 9 Paternal uncle - dementia, alcoholism
176 FTD-PPA 2 Mother - depression; Daughter - ADD
177 AD 3 Mother - LOAD; Father - alcoholism; Son - alcoholism
183 Possible
FTLD
2 Father PTSD & depression; mother DLB, mutism; mat
grandfather PD & stroke; maternal uncle DLB; 2 paternal
aunts with MND
194 Probable bv-
FTD
3 Sister - dementia; Father - stroke; Mother - depression ; Son -
depression/anxiety
195 Probable bv-
FTD
6 Mother - action tremor; Paternal grandmother - dementia;
maternal great grandmother dementia
199 Possible
FTLD
2 Father - dementia ; Daughter - seizures ; Maternal
grandmother - dementia
200 Probable bv-
FTD
6 Daughter - ADD, anxiety; Son - substance abuse
201 Possible
FTLD
4 Father- dementia in his 60’s, stroke; Sister - dementia; Brother
- stroke; Brother - epilespy, stroke; Son - epilepsy, mental
illness, grandfather dementia in his 60’s
203 Probable bv-
FTD
3 Paternal grandmother - late onset dementia at 91; Mother -
MS; maternal grandmother Parkinson’s onset at 78, maternal
great aunt and uncle late onset AD
205 Possible
FTLD
10 2 Sisters - anxiety; Sister - PSP; Daughter - eating disorder;
Daughter - anxiety, depression; Daughter - schizophrenia;
Son/2 Daughters - depression
207 Possible
FTLD
7 Siblings tremor, anxiety, alcoholism, substance abuse, mother
died at 83 had dementia and anxiety; father died at 79 had
Parkinson’s and anxiety.
209 Probable bv-
FTD
7 Father - stroke ; Brother - born w/hole in skull; Daughter -
seizure disorder
210 Possible
FTLD
7 Maternal grandfather - dementia
212 Probable bv-
FTD
5
215 Possible
FTLD
2 Mother - AD ; Father - dementia ; Brother - depression ; Son -
arthrogyrosis
216 Possible
FTLD
9 Sister - mild stroke, depression
217 Probable bv-
FTD
2 father died at age 82 no dementia but paternal grandfather
died of dementia at 81
218 Probable bv-
FTD
~ 25 Mother - dementia; Son - ALS; Maternal aunt - AD
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Patient
ID
Diagnosis Hexanucleotide
Repeats #
Family history of neurological disorders
219 Probable bv-
FTD
2 Daughter - anx, dep, neurocardiogenic syndrome ; Brothers -
depression ; Sister - anx, dep, ADHD ; Father - dementia ;
Mother - stroke
221 Probable bv-
FTD
10 Father - vascular dementia at 78
222 Possible
FTLD
2 Father - AD, PD, heart disease; Brother - alcohol abuse
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